(Q33456102)

26 July 2017

title

Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months (English)

1 reference

26 July 2017

1 reference

irritable bowel syndrome

1 reference

1 reference

E Safroneeva

2

0 references

author name string

P Meyrat

series ordinal

1

1 reference

26 July 2017

A M Schoepfer

series ordinal

3

1 reference

26 July 2017

language of work or name

English

0 references

publication date

16 October 2012

1 reference

Alimentary Pharmacology & Therapeutics

26 July 2017

published in

1 reference

26 July 2017

volume

36

1 reference

26 July 2017

issue

11-12

1 reference

26 July 2017

page(s)

1084-1093

1 reference

26 July 2017

cites work

Irritable bowel syndrome

1 reference

The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects.

21 January 2018

1 reference

Costs of irritable bowel syndrome in the UK and US.

21 January 2018

1 reference

Irritable bowel syndrome: toward an understanding of severity

21 January 2018

1 reference

The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects

21 January 2018

1 reference

Small intestinal bacterial overgrowth in patients with irritable bowel syndrome

21 January 2018

1 reference

Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis

21 January 2018

1 reference

A systematic review of diagnostic tests for small intestinal bacterial overgrowth

21 January 2018

1 reference

Evaluating a bacterial hypothesis in IBS using a modification of Koch's postulates: part 1.

21 January 2018

1 reference

Abnormal breath testing in IBS: a meta-analysis

21 January 2018

1 reference

Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

21 January 2018

1 reference

Rifaximin--a novel antimicrobial for enteric infections

21 January 2018

1 reference

Rifaximin therapy for patients with irritable bowel syndrome without constipation

21 January 2018

1 reference

The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis

21 January 2018

1 reference

Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth.

21 January 2018

1 reference

A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence

21 January 2018

1 reference

An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome

21 January 2018

1 reference

Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation

21 January 2018

1 reference

Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis

21 January 2018

1 reference

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors?

21 January 2018

1 reference

Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy

21 January 2018

1 reference

Proton pump inhibitor therapy use does not predispose to small intestinal bacterial overgrowth.

21 January 2018

1 reference

Effect of predominant methanogenic flora on the outcome of lactose breath test in irritable bowel syndrome patients

21 January 2018

1 reference

Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity

21 January 2018

1 reference

Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/APT.12087

1 reference

26 July 2017

1 reference